Published in Law and Health Weekly, November 27th, 2004
The phase I trials of CB7630 were conducted at the Cancer Research UK Centre for Cancer Therapeutics/Institute of Cancer Research and the Royal Marsden Hospital in the United Kingdom, and the results were published in the British Journal of Cancer in June, 2004.
The presentation, entitled "CB7630 (Abiraterone Acetate): A Novel Targeted Oral Therapy for Hormone-Refractory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.